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Temporal trends and outcomes of acute myocardial infarction in
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Background: Data on outcomes of ST-elevation myocardial infarction (STEMI) in patients with cancer
are scarce. We investigated the nationwide trends in admissions for STEMI, utilization of percutaneous
coronary intervention (PCI), and in-hospital outcomes in patients with the three most common cancer
diagnoses (lung, breast, and colon) compared to patients without cancer.
Methods: We conducted an administrative database study using the Nationwide Inpatient Sample (NIS).
All in-patient hospitalizations for STEMI from 2001 to 2011 were identified. Patients with concomitant
diagnosis of lung, breast or colon cancer were identified using appropriate International classification of
diagnosis (ICD 9-CM) codes. Primary outcome was utilization of PCI and in-hospital mortality in patients
with cancer compared to those without cancer.
Results: Utilization of PCI was 30.8% (1,191/3,871), 20.2% (4,541/22,480) and 17.3% (1,716/9,944) in
patients with breast, lung and colon cancer, respectively. Among patients without any of these cancers, use of
PCI was 49.6%. In-hospital mortality was highest in patients with lung cancer (57.1%) and lowest in patients
without cancer (25.7%).
Conclusions: Patients with cancer have significantly worse in-hospital mortality compared to those
without cancer, partly due to a relatively lower rate of PCI utilization in cancer patients with STEMI.
Keywords: Cancer; acute myocardial infarction; percutaneous coronary intervention (PCI)
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Introduction
Recent advances in cancer therapy have led to a significant
decline in cancer-related mortality. It is estimated that
there would be around 18 million cancer survivors in the
United States by 2020 (1). Improvement in life expectancy
in cancer patients, however, has led to an increase in burden
of cardiovascular disease in this cohort of patients, partly
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related to comorbidities and partly due to the use of cardio
toxic chemotherapeutic regimens. This has led to the
inception of cardio-oncology, with many centers developing
subspecialty programs to cater to the growing need of
these patients. However, the exclusion of cancer patients
from cardiovascular clinical trials and heart disease patients
from oncology investigations has resulted in a paucity of
data to direct clinical decision-making in many cardio-
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Figure 1 Graphical trends in STEMI incidence and in-hospital mortality in patients with and without cancer between 2001–2011. (A)
Trends in STEMI incidence from 2001–2011 among patients with various cancers (primary vertical axis) and general population without
cancer (secondary vertical axis); (B) trends in STEMI in-hospital mortality from 2001–2011. STEMI, ST-elevation myocardial infarction.

oncology patients (2). Further, patients with cancer present
with multiple comorbidities such as coagulopathy and
thrombocytopenia which make incorporation of existing
guideline -based treatments challenging. We sought to
identify trends in admissions for ST-elevation myocardial
infarction (STEMI), utilization of percutaneous coronary
intervention (PCI) and in-hospital outcomes in patients
with three common cancers (lung, breast, colon) compared
to patients without cancer.
Methods
We used the Nationwide Inpatient Sample (NIS) to identify
all admissions with ST elevation myocardial infarction
(ICD 9 code 410) from the years 2001–2011. The NIS is
part of the Agency for Health Care Research and Quality's
Healthcare Cost and Utilization Project (HCUP) and is
the largest all-payer inpatient care database in the United
States, containing data on >7 million hospital stays. It
contains data related to hospital admission and discharge
from a 20% stratified sample of community hospitals in
the United States (3). We used the clinical classification
software developed by HCUP to identify the clinical
variables for our analyses. Using this dataset, patients
with STEMI and a concurrent diagnosis of lung cancer,
colon cancer and breast cancer were identified. A cohort of
patients admitted for STEMI without any of these cancer
diagnoses was identified as the non-cancer group. We
evaluated utilization of PCI (angioplasty and/or stenting)
and in-hospital outcomes in STEMI patients with various
cancers. All statistical analyses were done using SAS
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9.4 (Cary, NC).
Results
There were 3,794,385 STEMI admissions during the study
period from 2001 to 2011 of which 5,552 (0.15%) patients
had active breast cancer, 31,246 (0.82%) had lung cancer
and 12,015 (0.32%) patients had colon cancer. Trends in
STEMI admissions have been declining in the general
population and patients with lung cancer, whereas patients
with breast and colon cancer demonstrated a stable trend
(Figure 1). Utilization of PCI was 30.8% (1,191/3,871),
20.2% (4,541/22,480), and 17.3% (1,716/9,944) in
patients with breast, lung and colon cancer, respectively
(Table 1). Comparatively, among patients without any of
these cancers, use of PCI was 49.5%. In-hospital mortality
was highest in patients with lung cancer (57.1%) and lowest
in patients without cancer (25.7%) with no significant
difference in trends (Figure 1). Utilization of PCI favorably
impacted in-hospital mortality in all patients’ groups
(Figure 2).
Discussion
In the present study, we report a significant incidence of
STEMI in patients with the three most prevalent cancers
in the United States. Although the incidence of STEMI
has been declining in the general population, incidence in
patients with breast and colon cancer has remained steady.
We also report a significant disparity in utilization of PCI
in patients with cancer presenting with STEMI compared
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Table 1 Utilization of PCI and in-hospital mortality in STEMI patients with and without cancer
Variables
No. of
patients

Breast cancer (N=3,871) (%)

Lung cancer (N=22,480) (%)

Colon cancer (N=9,944) (%)

PCI

No PCI

PCI

No PCI

PCI

No PCI

1,191 (30.8)

2,680 (69.2)

4,541 (20.2)

17,939 (79.8)

1,716 (17.3)

8,228 (82.7)

90 (7.6)

747* (27.9)

698 (15.4)

7,484* (41.7)

178 (10.4)

2,693* (32.7)

In-hospital
mortality

No cancer (N=2,990,913) (%)
PCI

No PCI

1,483,706 (49.6) 1,507,207 (50.4)
58,037 (3.9)

328,762* (21.8)

*, represents that there is a statistically significant difference in mortality between the PCI and no PCI groups with a P value of <0.001.
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
In-hospital mortality based on PCI utilization
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Figure 2 In-hospital mortality in patients with various cancers and
general population based on PCI utilization. *, P<0.001 for all of
the above comparisons in the chart. PCI, percutaneous coronary
intervention.

to the general population. Overall in-hospital mortality was
substantially higher in patients with cancer compared to the
non-cancer cohort. Even in the cancer cohort, utilization of
PCI had a substantial impact on immediate outcomes with
higher rates of in-hospital mortality in patients in whom
PCI was deferred. This could represent a wide practice
variation in the implementation of life saving therapies in
patients with cancer.
Coronary artery disease is a frequent comorbidity in
patients with various cancers. This is explained partly by
the improvement in therapeutic modalities for cancer
that prolong life expectancy and in part by direct cardiac
and vascular toxic effects of chemotherapy and radiation.
In addition, cancer patients have a hypercoagulable state
that predisposes to acute thrombotic events. Data on
outcomes of cancer patients with STEMI is sparse due to
the exclusion of these patients from randomized clinical
trials. A few existing registry studies have reported higher
mortality rates in patients with cancer presenting with acute
coronary syndrome. Velders et al. reported a multi-center
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study from the Netherlands on outcomes of STEMI in
patients with cancer (4). In this prospective registry, patients
with cancer had a higher incidence of cardiovascular
comorbidities such as peripheral vascular disease, renal
insufficiency and cerebrovascular disease. Use of drugeluting stents and glycoprotein IIb/IIIa inhibitors was
significantly lower in patients with cancer. Patients with
cancer who had STEMI had significantly higher all-cause
mortality at 1-year follow-up compared with those without
a history of cancer (in-hospital 9.1% vs. 3.4%, 1-year 17.4%
vs. 6.5%). More importantly, this difference in mortality
was primarily driven by a higher incidence of cardiac death
in cancer patients (in-hospital 8.7% vs. 3.4%, 1-year 10.7%
vs. 5.4%). The presence of cancer, specifically diagnosed
in 6 months preceding the STEMI, was an independent
risk factor for increased cardiac and all-cause mortality at
7 days on multivariate analysis (adjusted hazard ratio =3.34;
95% CI, 1.57–7.08). In a small observational series from
Japan, Kurisu et al. compared outcomes of acute MI in
patients with and without cancer and showed no difference
in coronary revascularization, discharge medications, stent
selection or cardiovascular outcomes between the two
groups (5). Yusuf et al. reported a single center experience
outcomes of 456 cancer patients with an acute coronary
syndrome (STEMI 15%) over a 6-year study period (6).
In their series, PCI was utilized in only 3.3% of cancer
patients, and the 1-year mortality was 78% in patients with
STEMI (6).
Patients with active cancer presenting with STEMI
represent a challenging cohort. Complications related to the
underlying cancer such as coagulopathy, thrombocytopenia,
anemia, organ dysfunction, and anticipation of other
therapeutic procedures factor into clinical decision making.
Patients with advanced cancer are particularly challenging
as long-term goals of care have to be considered. In a recent
expert consensus statement on the management of cancer
patients in the catheterization lab, it was recommended
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to consider PCI in cancer patients with STEMI and high
risk non-STEMI even when life expectancy is <1 year and
to use drug-eluting stents if the platelet count is above
30,000/mL (7). In addition to prolonging survival,
revascularization may also be a palliative option to control
symptoms in patients with severe angina pectoris.
Our study is the largest one reporting contemporary
outcomes of STEMI in cancer patients. Strengths of our
study include analysis of a nationwide cohort over a decade
and a large sample size. However, we acknowledge several
limitations. Data on cancer stage, treatment strategies,
hematological parameters, and anticipated procedures were
not available. All these factors may play a significant role in
decision making regarding PCI. We assessed only in-hospital
mortality, and data on long-term outcomes were unavailable.
In summary, we report a relatively lower rate of PCI
utilization in cancer patients with STEMI. With lack of
clinical trial data on management of STEMI in patients
with various cancers and with improvements in cancer
survivors overall, further studies are required to identify
gaps in knowledge in appropriate selection of cancer
patients for PCI.
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